ОСТЕОНЕКРОЗ ЧЕЛЮСТЕЙ КАК ОСЛОЖНЕНИЕ ТЕРАПИИ БИСФОСФОНАТАМИ В СТОМАТОЛОГИЧЕСКОЙПРАКТИКЕ

1. Руководство по остеопорозу (под редакцией Беневоленской Л.И.) Бином, Москва, 2010, 196—216.

2. Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled, clinical trials. J Clin Oncology 19:558, 2001.

3. Hillner BE, Ingle JN, Chelbowski RT, et.al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21:4042, 2003.

4. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458, 200.2

5. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006 May 16; 144(10):753—61. Erratum in: Ann Intern Med. 2006 Aug 1;145(3):235.

6. American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaws. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws. J Oral Maxillofac Surg 65:369, 2007.

7. Polizzotto MN, Cousins V, Schwarer AP. Bisphosphonate-associated osteonecro-sis of the auditory canal. Br J Haematol. 2006 Jan; 132(1):114.

8. Edwards BJ, Gounder M, McKoy JM et al. Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. Lancet Oncol. 2008; 9(12):1166—72.

9. Hohnecker JA. Novartis «Dear Doctor» Precautions added to label of Aredia and Zometa. September 24, 2004.

10. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61(9):1115—7.

11. Khosla S, Burr D, Cauley J et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res.2007;22(10):1479—91.

12. Coxon FP. An Update on the Pharmacology of Bisphosphonates and Analogues with Lower Bone Affinity. Bone. 2008,2, 203—207.

13. Allen R, Ruggiero S L. Osteonecrosis of the Jaw : Recent Clinical and Preclinical Advances. Bone.2011, 3,189—196.

14. Somerman J., McCauley L K. Bisphosphonates — Sacrifing the Jaw to Save the Skeleton? Martha J.Somerman, Bone.2006, 5, 378—397.

15. Woo SB, Hande K, Richardson PG. Osteonecrosis of the jaws and bisphosphonates [Letter]. N Engl J Med 353:100, 2005.

16. Cornish J, Bava U, Callon KE, Bai J, Naot D, Reid IR. Bone-bound bisphosphonate inhibits growth of adjacent non-bone cells. Bone. 2011 Oct; 49(4):710—6.

17. Marth J.Somerman, Laurie K.McCauley.Bisphosphonates — Sacrificing the Jaw to Save the Skeleton. Bone. 2010, 12, 109—112.

18. Jontell M, Landesberg R, Laslop A. Osteonecrosis of the Jaw and bisphosphonate treatment for osteoporosis.Bone. 2007,4,46—53.

19. Boyde A.Jaw Bone Necrosis and Bisphosphonates : Micro-anatomical Questions. Bone.2006, 4, 158-162.Bone. 3, 141—153.

20. Робустова Т.Г. Хирургическая стоматология.1996, 134—138.

21. Capsoni F, Longhi M. Bisphosphonate — associated osteonecrosis of the jaw: the rheumatologists role. Arthritis Research & Therapy. 2006, 8, 219

22. Allen M R, Burr D B. Mineralization, Microdamage, and Matrix: How Bisphosphonates Influence Material Properties of Bone. Bone.2007, 4(2), 49—60.

23. Perez S B, Barrero M V. Bisphosphonate — associated osteonecrosis of the jaw.MedOralPatolBucal. 2008,13 (12), 770.

24. Reid I.R. Pathogenesis of Osteonecrosis of the Jaw. Bone. 2009, 11, 178-186.

25. Otto S, Paulke C.Osteonecrosis of the Jaw, Bone.2009,4, 63-70.

26. Said F, Ghoul-Mazgar S, Khemiss F, El Ayeb H, Saidane D, Berdal A. The effect bisphosphonates on the periodontium of ovari-oectomized rats.J Periodontol. 2012 Aug;83(8):1063—8.